Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Efalizumab

Nature Reviews Drug Discovery volume 3, pages 473–474 (2004)Cite this article

Abstract

Efalizumab (Raptiva; Genentech/Xoma/Serono) is a monoclonal antibody that binds to CD11a, a cell-surface protein that has a key role in the pathological immune response in the skin disorder psoriasis. Following its approval by the FDA in October 2003 for the treatment of moderate-to-severe psoriasis, how is efalizumab likely to fare in this increasingly competitive market?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mode of action of efalizumab.
Figure 2: Market for drugs to treat psoriasis in 2001 in US $ million.

References

  1. Greaves, M. W. & Weinstein, G. D. Treatment of psoriasis. N. Engl. J. Med. 332, 581–588 (1995).

    Article  CAS  Google Scholar 

  2. Christophers, E. Psoriasis — epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26, 314–320 (2001).

    Article  CAS  Google Scholar 

  3. Krueger, J. G. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46, 1–23 (2002).

    Article  Google Scholar 

  4. Werther, W. A. et al. Humanization of an anti-lymphocyte function associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157, 4986–4995 (1996).

    CAS  PubMed  Google Scholar 

  5. FDA labelling information [online] (cited 22 March 2004) <http://www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf> (2003).

  6. Lebwohl, M. et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349, 2004–2013 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

  2. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Sylvia Marecki

Authors
  1. Sylvia Marecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sylvia Marecki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marecki, S., Kirkpatrick, P. Efalizumab. Nat Rev Drug Discov 3, 473–474 (2004). https://doi.org/10.1038/nrd1420

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1420

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing